In the TCGA BLCA cohort with low hypoxia risk scores, Rb1 showed co-mutation with TP53 and ARID1A, and Rb1 had a mutually exclusive mutation with FGFR3. This evidence concerns the gene FGFR3 and bladder transitional cell carcinoma.